News

Labcorp Plans Nationwide Access to FDA-Approved BD Onclarity HPV Testing

Labcorp plans to expand access to extended-genotyping HPV testing through clinic, patient service center, and at-home screening options

Written byMiriam Bergeret, MSc
| 2 min read
Bright and spacious clinic waiting room at a HPV testing clinic.
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Waters Corporation and Labcorp have announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network, with availability planned by the end of 2026. The collaboration aims to address gaps in cervical cancer screening by offering clinician-collected and self-collected testing options across clinical settings, patient service centers, and at-home channels.

Cervical cancer is largely preventable through routine screening and early detection of human papillomavirus (HPV), yet millions of women remain overdue for recommended testing, according to the announcement. Adding to these concerns, the proportion of US women who have never undergone cervical cancer screening has increased substantially in recent years, particularly among women aged 21 to 29.

The expanded screening options are intended to help reach people who face barriers related to privacy, access, and socioeconomic circumstances.

Labcorp serves more than 850,000 physicians and healthcare providers and operates more than 2,200 patient service centers. The company plans to offer the testing options through clinician programs, health plan Gaps in Care programs, and consumer channels, including Labcorp OnDemand.

“Barriers such as privacy, access, and socioeconomic factors can make it difficult to stay current with cervical cancer screening,” said Jeff Andrews, MD, FRCSC, vice president of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation. “We are at the start of a new era in which screening can extend beyond the clinic, enable more personalized risk assessment, and reach people who have historically been underserved. By offering greater flexibility in how and where people are screened, our collaboration marks a critical step forward in bridging one of today’s most profound care gaps.”

Extended genotyping supports risk assessment

The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, according to Waters and Labcorp.

Certain HPV genotypes, including types 16, 18, and 45, are associated with increased cervical cancer risk, making genotype-specific information important for patient management. The assay individually identifies six high-risk HPV types—16, 18, 31, 45, 51, and 52—and provides results for three additional strategically pooled groups. The company states that this extended genotyping capability is available regardless of the specimen collection method.

The announcement also highlights changes in the distribution of high-risk HPV infections. As HPV vaccination has reduced infections from types 16 and 18, other high-risk HPV strains account for a growing share of cervical disease, particularly among younger, vaccinated populations. Extended genotyping can provide more detailed information about the HPV types detected to help inform clinical management.

“Cervical cancer screening saves lives, but too many women still face barriers to getting screened,” said Dr. Brian Caveney, chief medical and scientific officer, Labcorp. “By expanding access and options for comprehensive FDA-approved HPV testing, we can help more women stay current with recommended screening, reach those who may be overdue for care, and support earlier identification of cervical cancer risk.”

The BD Onclarity HPV Assay is expected to become available through Labcorp by the end of 2026.

This article was created with the assistance of Generative AI and has undergone editorial review before publishing.

Frequently Asked Questions (FAQs)

  • Why is cervical cancer screening important?

    Cervical cancer screening is crucial for early detection of HPV, which can lead to cervical cancer. Regular screenings can significantly reduce the risk of developing cervical cancer, yet many women are overdue for testing.

  • What role does HPV genotyping play in cervical cancer risk assessment?

    HPV genotyping provides detailed information about specific high-risk HPV types, which is essential for assessing individual risk and informing clinical management decisions related to cervical cancer.

  • How will the partnership between Waters Corporation and Labcorp improve cervical cancer screening?

    The partnership aims to expand access to the BD Onclarity HPV Assay by offering a variety of testing options, including clinician-collected and self-collected tests, across multiple settings, which can help address barriers to screening.

  • What is the FDA-approved BD Onclarity HPV Assay?

    The BD Onclarity HPV Assay is an FDA-approved test designed for the detection of human papillomavirus (HPV) that supports a comprehensive approach to cervical cancer screening, including genotyping for high-risk HPV types.

  • When will the BD Onclarity HPV Assay be available through Labcorp?

    The BD Onclarity HPV Assay is expected to become available through Labcorp's nationwide network by the end of 2026.

Add Today's Clinical Lab as a preferred source on Google

Add Today's Clinical Lab as a preferred Google source to see more of our trusted coverage.

About the Author

  • Photo portrait of Miriam Bergeret

    Miriam Bergeret, MSc, is Today's Clinical Lab's managing editor. Before joining Today's Clinical Lab, Miriam obtained an MSc in laboratory medicine and pathobiology from the University of Toronto and gained valuable laboratory experience as a flow cytometry and cell-sorting specialist at a cancer research center in Toronto, Canada. Miriam went on to study publishing at Toronto Metropolitan University and is an active member of Editors Canada and the Council of Science Editors.

    View Full Profile

Related Topics

Loading Next Article...
Loading Next Article...